Claims data spanning 4 years were obtained from a pediatric accountable care organization.
There is as much as a 32% risk for vigabatrin-associated brain abnormalities in patients with infantile spasms.
Greater spasm cessation was achieved in the combination group vs those who received hormonal therapy alone.
Shaun Hussain, MD, MS, discusses a gap in health care provider knowledge that may contribute to the delay in the diagnosis and treatment of infantile spasms.
Less than 30% of patients were seen by an effective provider within 1 week of onset of infantile spasms.
Long-term use of pharmacological treatments are associated with adverse events.
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Early Clinical Traits of Multiple Sclerosis Prodrome Identified
- Chronic Pain May Be Contributor to Suicide
- Ajovy Injection Approved for Migraine Prevention in Adults
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies
- Familial Hemiplegic Migraine Attacks May Be Associated With Cortical Swelling
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Fremanezumab May Have Long-Term Efficacy as a Prophylactic for Chronic Migraine
- Propofol May Decrease Delay in Neurocognitive Recovery